Ascelia Pharma Future Growth

Future criteria checks 0/6

Ascelia Pharma is forecast to grow earnings and revenue by 40.8% and 70.1% per annum respectively. EPS is expected to decline by 14.3% per annum. Return on equity is forecast to be -36.9% in 3 years.

Key information

40.8%

Earnings growth rate

-14.3%

EPS growth rate

Biotechs earnings growth	27.2%
Revenue growth rate	70.1%
Future return on equity	-36.9%
Analyst coverage	Low
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:ACES - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2024	103	-171	-186	-186	2
12/31/2023	N/A	-212	-216	-215	2
12/31/2022	N/A	-140	-141	-141	2
6/30/2022	N/A	-115	-127	-127	N/A
3/31/2022	N/A	-126	-125	-125	N/A
12/31/2021	N/A	-126	-117	-117	N/A
9/30/2021	N/A	-127	-112	-112	N/A
6/30/2021	N/A	-113	-100	-100	N/A
3/31/2021	N/A	-111	-90	-90	N/A
12/31/2020	N/A	-99	-86	-86	N/A
9/30/2020	N/A	-90	-75	-75	N/A
6/30/2020	N/A	-88	-76	-76	N/A
3/31/2020	N/A	-71	-70	-70	N/A
12/31/2019	N/A	-66	-54	-54	N/A
9/30/2019	N/A	-46	-47	-47	N/A
6/30/2019	N/A	-37	-30	-30	N/A
3/31/2019	N/A	-30	-19	-19	N/A
12/31/2018	N/A	-23	-19	-19	N/A
9/30/2018	N/A	-22	-17	-17	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACES is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACES is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACES is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACES is forecast to have no revenue next year.

High Growth Revenue: ACES is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ACES is forecast to be unprofitable in 3 years.

Ascelia Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Ascelia Pharma AB (publ) Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study

Ascelia Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 07, 2025

Ascelia Pharma AB (publ) Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE

Ascelia Pharma AB (publ) Announces 71 Patients Have Completed the SPARKLE Study

Ascelia Pharma AB (Publ) Announces 65 Patients Completes the Sparkle Study

Ascelia Pharma AB (Publ) Announces New Data Show That the Pivotal Phase 3 Clinical Sparkle Study

Ascelia Pharma AB Announces That the Nomination Committee in Preparation for the Annual General Meeting on 4 May 2023 Has Been Appointed

Ascelia Pharma Presents Results of Orviglance Food Effect Study At RSNA 2022 Showing Strong Liver Enhancement Both with Light Meal and in Fasting Condition

Ascelia Pharma AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Ascelia Pharma AB (Publ) Announces Resignation of Carl Bjartmar as CMO

Ascelia Pharma AB (publ) Announces Successful Final Results from Orviglance Hepatic Impairment Study

Ascelia Pharma AB (publ) Announces Change of CFO

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies